Presentation is loading. Please wait.

Presentation is loading. Please wait.

Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis  Anja Gunda Jung, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Tobias Overbeck,

Similar presentations


Presentation on theme: "Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis  Anja Gunda Jung, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Tobias Overbeck,"— Presentation transcript:

1 Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis 
Anja Gunda Jung, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Tobias Overbeck, MD, Michael Peter Schön, MD, Undine Lippert, MD  Journal of the American Academy of Dermatology  Volume 65, Issue 1, Pages (July 2011) DOI: /j.jaad Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 A, Reddish papules on the chest before treatment (overall involvement: 15% of the body surface with a 20% density). B, Reddish papules on the chest after 14 months of treatment with imatinib mesylate (overall involvement: 15% of the body surface with a 10% density). The extent of surface involvement was assessed as in burns. The density was calculated in the most affected area as percent lesional skin surface to total skin surface. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Radiographic scan of the left humerus showing nonhomogeneously distributed multiple areas of osteolysis emphasized in the proximal and distal third of the humerus. Arrows show osteolysis. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2009 American Academy of Dermatology, Inc. Terms and Conditions


Download ppt "Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis  Anja Gunda Jung, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Tobias Overbeck,"

Similar presentations


Ads by Google